Galafold 123 MG capsule - NTE
Active Awarded Last action
- Contract number
- 36C25926F0001
- Awardee
-
Amicus Therapeutics US, LLC UEI KLJFGENKMD89
- Awarding agency
-
Veterans Integrated Service Network 19
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $295,018
Award facts
- Contract value 100% obligated
- $295,018.13 Current and potential, with all options
- Completion date 93% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19104, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $10,432 | |
| Original award | $284,586 |
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 19, awarded a delivery order to Amicus Therapeutics US, LLC for Galafold 123 mg capsules valued at $295,018.13. This firm fixed-price delivery order, issued on November 15, 2025, with an ultimate completion date of November 14, 2026, represents a child task order under the parent Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract (36F79724D0185), valued at $13.02 million and effective through August 31, 2029. The delivery order contains no set-aside designation and specifies performance at a facility located in Philadelphia, Pennsylvania. Amicus Therapeutics US, LLC is a biopharmaceutical subsidiary specializing in treatments for rare genetic diseases, and Galafold (migalastat) is an FDA-approved enzyme replacement therapy indicated for Fabry disease treatment.
This award continues an extensive procurement pattern spanning since March 2021, during which Amicus Therapeutics US, LLC has fulfilled over 150 delivery orders across multiple Veterans Integrated Service Networks, including VISN 5, 7, 9, 19, and 21. The company operates exclusively as a prime contractor with no subcontractor involvement, ensuring direct control over the supply chain for this critical specialty pharmaceutical. Task orders under this FSS contract vehicle typically reflect routine pharmaceutical supply requirements and emergency pharmacy purchases, with performance periods often completed within weeks of award. The consistent utilization of firm fixed-price mechanisms and widespread geographic distribution across VA regions demonstrates the essential role of Galafold within the Veterans Health Administration's specialized healthcare services for veterans with Fabry disease.
Quick answers
Who was awarded contract 36C25926F0001?
36C25926F0001 was awarded to Amicus Therapeutics US, LLC by Veterans Integrated Service Network 19 (Veterans Health Administration) on November 15, 2025.
How much is contract 36C25926F0001 worth?
The government has obligated $295,018 on 36C25926F0001.
Is contract 36C25926F0001 an order under another contract?
Yes. 36C25926F0001 is a delivery order under 36F79724D0185, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25926F0001 competed?
The extent of competition for 36C25926F0001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award